Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

By Pilotto Sara   Bria Emilio  

Lung Cancer Management, Vol. 2, Iss. 2, 2013-04 ,pp. : 89-92

Future Medicine

Access to resources Recommend Favorite

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: Implication of EGFR tyrosine kinase inhibitors

By                            

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 685-692

Spandidos Publications

Access to resources Recommend Favorite

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation

By                

Molecular Medicine Reports, Vol. 11, Iss. 4, 2015-01 ,pp. : 2767-2774

Spandidos Publications

Access to resources Recommend Favorite

Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1499-1504

Spandidos Publications

Access to resources Recommend Favorite

A peptide antigen derived from EGFR T790M is immunogenic in nonsmall cell lung cancer

By  

International Journal of Oncology, Vol. 46, Iss. 2, 2015-01 ,pp. : 497-504

Spandidos Publications

Access to resources Recommend Favorite